Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Core Viewpoint - ClaimsFiler is reminding investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics, related to undisclosed material information during the Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Corcept and its executives failed to disclose material information, violating federal securities laws during the Class Period from October 31, 2024, to December 30, 2025 [3]. - The complaint specifically mentions that Corcept misled investors regarding the likelihood of FDA approval for its product candidate, relacorilant, following its New Drug Application submission [4]. - Following the disclosure of a Complete Response Letter from the FDA on December 31, 2025, which indicated that additional evidence of effectiveness was needed, Corcept's share price fell by $35.40, or 50.4%, from $70.20 to $34.80 [4]. Group 2: Legal and Investor Support - The case is officially titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 [5]. - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6].